Literature DB >> 19131308

Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass.

R Clive Landis1, Joseph E Arrowsmith, Robert A Baker, Filip de Somer, Wojciech B Dobkowski, Gregory Fisher, Richard A Jonas, Donald S Likosky, John M Murkin, Michael Poullis, David A Stump, Edward D Verrier.   

Abstract

The causal factors of the systemic inflammatory response to cardiopulmonary bypass (CPB) were correctly identified in the early 1990 s: "... activation of complement, coagulation, fibrinolytic, and kallikrein cascades, activation of neutrophils with degranulation and protease enzyme release, oxygen radical production, and the synthesis of various cytokines from mononuclear cells" [Butler 1993]. Why therefore have clinical advances to curb the systemic inflammatory response proven such a disappointment? Part of the problem is that cardiac surgery has never taken intellectual ownership of this issue, borrowing its diagnosis from critical care medicine and failing to define the minimal criteria that should be measured when reporting on the systemic inflammatory response. An evidence based review of the current literature by many of the coauthors on this paper found that the majority of studies on the systemic inflammatory response did not measure a single one of the causal factors listed above - thus hindering our ability to identify mechanisms of causation and identify drug targets [Landis 2008]. A panel of experts convened at the Outcomes XII meeting, Barbados 2008, drafted the present consensus document in order to provide a framework to guide future studies and interdictions of the systemic inflammatory response. Herein, we have recommended: 1) mandatory reporting of minimal CPB and perfusion criteria that may affect outcomes, 2) reporting of a minimal set of causal inflammatory markers linked to adverse sequelae, and 3) reporting of at least one clinical end-point of organ injury, from a list of endpoints and markers of organ injury that balance practicality with clinical meaningfulness. It is our collective belief that this document will serve as a foundation for furthering our understanding of the influence of CPB practice with the systemic inflammatory response by standardizing the reporting of research findings in the peer-reviewed literature.

Entities:  

Mesh:

Year:  2008        PMID: 19131308     DOI: 10.1532/HSF98

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  6 in total

1.  Lissajous figures: an engineering tool for root cause analysis of individual cases--a preliminary concept.

Authors:  Kenneth Palmer; Tim Ridgway; Omar Al-Rawi; Ian Johnson; Michael Poullis
Journal:  J Extra Corpor Technol       Date:  2011-09

2.  Clinical efficacy of two-phase leukocyte filtration in high-risk patients undergoing coronary revascularization with cardiopulmonary bypass.

Authors:  Serdar Gunaydin; Thomas Modine; Tamer Sari; Yaman Zorlutuna; Terence Gourlay
Journal:  J Extra Corpor Technol       Date:  2009-09

3.  Patient directed perfusion pressure on bypass, an analogy from electrical engineering--a new concept.

Authors:  Richard Warwick; Robert Poole; Kenneth Palmer; Ian Johnson; Michael Poullis
Journal:  J Extra Corpor Technol       Date:  2010-03

4.  Anti-inflammatory effect of aprotinin: a meta-analysis.

Authors:  Jeremiah R Brown; Andrew W J Toler; Robert S Kramer; R Clive Landis
Journal:  J Extra Corpor Technol       Date:  2009-06

5.  Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.

Authors:  Sasa Rajsic; Benedikt Treml; Dragana Jadzic; Robert Breitkopf; Christoph Oberleitner; Marina Popovic Krneta; Zoran Bukumiric
Journal:  Ann Intensive Care       Date:  2022-10-05       Impact factor: 10.318

6.  Association between preoperative plasma sRAGE levels and recovery from cardiac surgery.

Authors:  Benedict C Creagh-Brown; Gregory J Quinlan; Lauren R Hector; Timothy W Evans; Anne Burke-Gaffney
Journal:  Mediators Inflamm       Date:  2013-09-05       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.